Why the study?
Does the zotarolimus-eluting stent (Resolute Integrity) provide comparable safety and efficacy to other stents in patients with coronary artery disease?
Does the zotarolimus-eluting stent (Resolute Integrity) provide comparable safety and efficacy to other stents in patients with coronary artery disease?
The Resolute Integrity zotarolimus-eluting stent demonstrates noninferiority to other stents and may be suitable for treating complex coronary lesions.
May support Resolute Integrity in complex lesions; leaves open need for contemporary RCTs.
The need to develop a local antirestenotic mechanism to prevent in-stent thrombosis has driven the development of new generation stents. The Resolute Integrity ® stent is a zotarolimus-eluting system with a new BioLinx™ polymer that allows a slower drug elution. Recently available data has shown the clinical efficacy and safety of this stent in randomized and observational studies. The Resolute Integrity stent system has demonstrated noninferiority when compared with other stents and holds the promise to treat more complex coronary lesions.
No takes yet. Share an insight, caveat, or question.
Mukherjee et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: